Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 27, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Sumant Kulkarni Maintained (BTAI) at Strong Buy and Held Target at $7 on, Jun 27th, 2024
Sumant Kulkarni of Canaccord Genuity, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $7 on, Jun 27th, 2024.
Sumant has made no other calls on BTAI in the last 4 months.
There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Sumant's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Sumant
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $10 on, Friday, May 10th, 2024
- Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $7 on, Wednesday, March 13th, 2024
